Nebenwirkungen · Prometax
Prometax 4.6 mg/24 h transdermal patch Prometax 9.5 mg/24 h transdermal patch Prometax 13.3 mg/24 h transdermal patch · Abschnitt 4.8 · PDF-Seite 38
HOS-090185 · Präparat HOS-084005
In two 24-week double-blind, placebo-controlled clinical trials, skin reactions were measured at each visit using a skin irritation rating scale. When observed in patients treated with Prometax transdermal patches, skin irritation was mostly slight or mild in severity. It was rated as severe in ≤2.2% of patients in these studies and in ≤3.7% of patients treated with Prometax transdermal patches in a Japanese study.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-15T14:03:00Z · SHA-256 84780fda687229b6eb4fb8cc5e55f033116dac099756163d6052747dd50b9054 · Passage e3339f04cf635c62292b1293c94028dd501936f85280b8157df0705509063a46 · Zeichen 4650–5068 im Abschnitt